358 related articles for article (PubMed ID: 12501885)
21. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
Menzin J; Colditz GA; Regan MM; Richner RE; Oster G
Arch Intern Med; 1995 Apr; 155(7):757-64. PubMed ID: 7695464
[TBL] [Abstract][Full Text] [Related]
22. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
Gordois A; Posnett J; Borris L; Bossuyt P; Jönsson B; Levy E; de Pouvourville G
J Thromb Haemost; 2003 Oct; 1(10):2167-74. PubMed ID: 14521600
[TBL] [Abstract][Full Text] [Related]
23. [Economic analysis of dalteparin use in knee surgery at Instituto Mexicano del Seguro Social].
Arreola-Ornelas H; Rosado-Buzzo A; García-Mollinedo L; Dorantes Aguilar J; Muciño-Ortega E; Mould-Quevedo JF
Cir Cir; 2012; 80(5):411-8. PubMed ID: 23351443
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Lefebvre P; Coleman CI; Bookhart BK; Wang ST; Mody SH; Tran KN; Zhuo DY; Huynh L; Nutescu EA
J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma.
Devlin JW; Petitta A; Shepard AD; Obeid FN
Pharmacotherapy; 1998; 18(6):1335-42. PubMed ID: 9855335
[TBL] [Abstract][Full Text] [Related]
26. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
McCullagh L; Tilson L; Walsh C; Barry M
Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
[TBL] [Abstract][Full Text] [Related]
27. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
Dranitsaris G; Stumpo C; Smith R; Bartle W
Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
[TBL] [Abstract][Full Text] [Related]
28. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
[TBL] [Abstract][Full Text] [Related]
29. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.
Honorato J; Gómez-Outes A; Navarro-Quilis A; Martínez-González J; Rocha E; Planès A
Pharmacoeconomics; 2004; 22(13):885-94. PubMed ID: 15329033
[TBL] [Abstract][Full Text] [Related]
30. Economic Evaluation of Rivaroxaban Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Knee Replacement and Total Hip Replacement: A Systematic Review.
Rashki Kemmak A; Abutorabi A; Alipour V
Clin Drug Investig; 2020 Aug; 40(8):715-725. PubMed ID: 32578155
[TBL] [Abstract][Full Text] [Related]
31. [Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].
Gómez-Cerezo JF; Gómez-Arrayás I; Suárez-Fernández C; Betegón-Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Cir Ortop Traumatol; 2012; 56(6):459-70. PubMed ID: 23594943
[TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
Pharmacoeconomics; 2012 Feb; 30(2):87-101. PubMed ID: 22187932
[TBL] [Abstract][Full Text] [Related]
33. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
34. Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery.
Saunders ME; Grant RE
J Natl Med Assoc; 1998 Nov; 90(11):677-80. PubMed ID: 9828582
[TBL] [Abstract][Full Text] [Related]
35. Are factor Xa inhibitors effective thromboprophylaxis following hip fracture surgery?: A large national database study.
Campbell ST; Bala A; Jiang SY; Gardner MJ; Bishop JA
Injury; 2017 Dec; 48(12):2768-2772. PubMed ID: 29102371
[TBL] [Abstract][Full Text] [Related]
36. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
Jugrin AV; Ustyugova A; Urbich M; Lamotte M; Sunderland T
Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227
[TBL] [Abstract][Full Text] [Related]
37. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
de Lissovoy G; Subedi P
Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
[TBL] [Abstract][Full Text] [Related]
38. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
Fitzgerald RH; Spiro TE; Trowbridge AA; Gardiner GA; Whitsett TL; O'Connell MB; Ohar JA; Young TR;
J Bone Joint Surg Am; 2001 Jun; 83(6):900-6. PubMed ID: 11407799
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece.
Gourzoulidis G; Kourlaba G; Kakisis J; Matsagkas M; Giannakoulas G; Gourgoulianis KI; Vassilakopoulos T; Maniadakis N
Clin Drug Investig; 2017 Sep; 37(9):833-844. PubMed ID: 28608312
[TBL] [Abstract][Full Text] [Related]
40. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
Mahmoudi M; Sobieraj DM
Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
